Short answer · Medically reviewed summary · Last updated: 2026-05-08
Hyperekplexia, also known as startle disease, was first formally characterized in the mid-20th century, though it was historically misdiagnosed as epilepsy due to the dramatic nature of its symptoms. Today, we understand Hyperekplexia as a hereditary neurological disorder caused by mutations in glycine receptor genes, a discovery that revolutionized both diagnosis and clinical management. When was Hyperekplexia first described? While clinicians had observed hyper-reactive startle responses for decades, the first comprehensive clinical description of Hyperekplexia appeared in 1958 by Dr.
What is the history of Hyperekplexia?
History of Hyperekplexia: when and how it was discovered, and the milestones in research since, medically reviewed.
Hyperekplexia, also known as startle disease, was first formally characterized in the mid-20th century, though it was historically misdiagnosed as epilepsy due to the dramatic nature of its symptoms. Today, we understand Hyperekplexia as a hereditary neurological disorder caused by mutations in glycine receptor genes, a discovery that revolutionized both diagnosis and clinical management.
When was Hyperekplexia first described?
While clinicians had observed hyper-reactive startle responses for decades, the first comprehensive clinical description of Hyperekplexia appeared in 1958 by Dr. Kok and Dr. Bruyn. Initially, they referred to the condition as "familial myoclonus," highlighting its hereditary nature. It was later renamed Hyperekplexia—derived from the Greek for "excessive startle"—to more accurately capture the clinical presentation of exaggerated responses to auditory or tactile stimuli.
How has our understanding of Hyperekplexia evolved?
For many years, patients with Hyperekplexia were frequently misdiagnosed with epilepsy or cerebral palsy because the sudden, rigid posturing can mimic tonic seizures. The major turning point occurred in the early 1990s when researchers identified the genetic basis of the disorder. We now know that Hyperekplexia is primarily caused by mutations in the GLRA1 gene, which encodes a subunit of the glycine receptor, essential for proper inhibitory neurotransmission in the central nervous system.
What are the major milestones in treatment and genetics?
The shift from treating the condition as a seizure disorder to managing it as a neurotransmitter receptor defect has been profound. Key milestones include:
- 1958: Initial clinical characterization by Kok and Bruyn.
- 1993: Discovery of the GLRA1 gene mutation, confirming Hyperekplexia as a genetic channelopathy.
- Clinical Management: The identification of clonazepam as the gold-standard treatment, which works by enhancing the inhibitory effects of GABA.
- Advocacy: The rise of digital communities, such as the 56 members on DiseaseMaps.org, which have helped patients share experiences and reduce the isolation caused by rare disease stigma.
Next steps
- Consult with a neurologist specializing in movement disorders to confirm a diagnosis.
- Seek genetic counseling to understand the inheritance pattern, which can be autosomal dominant or recessive.
- Connect with the community of 56 patients on DiseaseMaps.org to share management strategies.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Hyperekplexia.
- Orphanet: Rare disease database entry for hereditary hyperekplexia.
- OMIM (Online Mendelian Inheritance in Man): Entry #149400 (Hyperekplexia 1).
- PubMed: Review of clinical phenotypes and genetic basis of Hyperekplexia.
